A detailed history of Assenagon Asset Management S.A. transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 173,714 shares of COLL stock, worth $5.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
173,714
Previous 362,137 52.03%
Holding current value
$5.2 Million
Previous $11.7 Million 42.44%
% of portfolio
0.01%
Previous 0.03%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$31.4 - $39.07 $5.92 Million - $7.36 Million
-188,423 Reduced 52.03%
173,714 $6.71 Million
Q2 2024

Jul 18, 2024

BUY
$31.36 - $39.99 $9.13 Million - $11.6 Million
291,286 Added 411.12%
362,137 $11.7 Million
Q1 2024

Apr 24, 2024

SELL
$31.23 - $40.91 $8.59 Million - $11.2 Million
-274,989 Reduced 79.51%
70,851 $2.75 Million
Q4 2023

Jan 17, 2024

SELL
$21.16 - $30.8 $1.69 Million - $2.46 Million
-79,790 Reduced 18.75%
345,840 $10.6 Million
Q3 2023

Nov 06, 2023

BUY
$21.23 - $24.28 $5.79 Million - $6.62 Million
272,565 Added 178.07%
425,630 $9.51 Million
Q2 2023

Jul 25, 2023

SELL
$21.06 - $24.0 $2.22 Million - $2.54 Million
-105,625 Reduced 40.83%
153,065 $3.29 Million
Q1 2023

Apr 18, 2023

BUY
$23.0 - $29.88 $2.9 Million - $3.76 Million
125,956 Added 94.89%
258,690 $6.21 Million
Q4 2022

Jan 12, 2023

BUY
$16.14 - $23.55 $1.9 Million - $2.78 Million
117,900 Added 794.8%
132,734 $3.08 Million
Q3 2022

Oct 27, 2022

SELL
$15.46 - $20.1 $549,819 - $714,836
-35,564 Reduced 70.57%
14,834 $238,000
Q1 2022

Apr 25, 2022

BUY
$17.2 - $22.5 $866,845 - $1.13 Million
50,398 New
50,398 $1.03 Million

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.02B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.